Insuman Comb 25

Insulin Human, the active ingredient in Insuman Comb 25, is an insulin presented as a premixed injectable solution for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients, providing basal and prandial glucose control.

GNH USA supplies Insuman Comb 25 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 25 is an insulin preparation used to manage hyperglycaemia in diabetes mellitus.

- Type 1 diabetes mellitus: provides both basal and mealtime insulin to maintain target blood‑glucose levels. - Type 2 diabetes mellitus: complements oral agents or other insulins when additional glucose control is required. - Insulin deficiency states (e.g., post‑pancreatectomy): replaces absent endogenous insulin to prevent hyperglycaemia.

Common Side Effects: - Hypoglycaemia: low blood‑glucose episodes, especially if meals are missed or dosing is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: due to improved glucose utilisation and storage. - Lipodystrophy: localized fat accumulation or loss at injection sites. - Edema: mild peripheral fluid retention.

Serious or Rare Side Effects: - Severe hypoglycaemia with seizures or loss of consciousness. - Allergic reactions including anaphylaxis or urticaria. - Insulin antibody formation leading to unpredictable glucose control. - Lipohypertrophy causing painful nodules. - Acute metabolic acidosis in rare cases.

Insuman Comb 25 requires careful monitoring and patient education. - Renal impairment: adjust dose and monitor glucose closely. - Hepatic dysfunction: consider more frequent glucose checks. - Pregnancy: use only if benefits outweigh risks and under medical supervision. - Concomitant beta‑blockers: may mask hypoglycaemia symptoms. - Do not mix with other insulin formulations in the same syringe. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 25 may interact with several drug classes.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: additive risk of severe hypoglycaemia. - Beta‑blockers: can mask hypoglycaemia warning signs. - Corticosteroids: may increase glucose levels, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood‑glucose modestly. - ACE inhibitors: may enhance insulin sensitivity, necessitating monitoring. - Oral contraceptives: may slightly affect insulin requirements.